Lewis T Williams
CIK 1475714 · Executive Chairman · last filed 2026-02-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.78M
Companies
6
Total Filings
70
Lifetime Open-Market Net
-$16.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTGX | Director | 25,825 | $146.49 | $3.78M | -$1.48M | 11 | 2026-02-18 |
| Arcellx, Inc. (ACLX) Delisted | Director | 2,095,114 | $115.07 | $241.08M | $0 | 1 | 2022-02-09 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 3 | 2021-05-13 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | 455,336 | $178.75 | $81.39M | -$1.51M | 19 | 2019-09-04 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | President, CEO and Chairman | 421,828 | $38.00 | $16.03M | -$13.49M | 20 | 2016-05-13 |
| BECKMAN COULTER INC (BEC) Delisted | Director | 1,372 | — | — | $0 | 14 | 2011-06-22 |
Recent Filings · Page 3 of 7
70 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-09-05 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Tax (F) | −7,024 | -$98.3K | EDGAR |
| 2018-06-12 | PTGX | Grant (A) | — | $0 | EDGAR |
| 2018-02-28 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2018-02-13 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Gift (G) | — | $0 | EDGAR |
| 2018-02-13 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Mixed | −55,029 | -$1.46M | EDGAR |
| 2018-02-07 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Tax (F) | −3,137 | -$57.8K | EDGAR |
| 2017-09-06 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Tax (F) | −7,827 | -$268.8K | EDGAR |
| 2017-06-15 | PTGX | Grant (A) | — | $0 | EDGAR |
| 2017-03-03 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Tax (F) | −34,532 | -$1.55M | EDGAR |
| 2017-02-09 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Mixed | −5,541 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.